Sylvia Shaw, MD
Endocrinology, Diabetes & Metabolism · Lynwood, CANPI 1093726663
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $957 of the $1,304 with a category attached, or 73.4%. Novo Nordisk AS accounts for 90.5% of it on its own, with 3 other manufacturers making up the rest. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 8 payments — averaging $163.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1K
- Lilly USA, LLC$89
- Shionogi Inc$19
- Astellas Pharma US Inc$16
Across 9 payments — averaging $9543.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$69K
- Janssen Research & Development, LLC$11K
- Sanofi US Services Inc.$5K
- AbbVie$1K
What the payments were for
- Travel & lodging$95773%
- Food & beverage$34727%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,180 |
| Lilly USA, LLC | 2 | $89 |
| Shionogi Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$1,101
How this compares
$1,304 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Lynwood
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.